Ebrahim Variava to Rifampin
This is a "connection" page, showing publications Ebrahim Variava has written about Rifampin.
Connection Strength
1,309
-
Occult rifampicin-resistant tuberculosis: better assays are needed. Lancet Infect Dis. 2018 12; 18(12):1293-1295.
Score: 0,562
-
Evolving therapies for rifampicin-resistant tuberculosis: balancing efficacy and toxicity. Lancet Respir Med. 2020 04; 8(4):326-328.
Score: 0,155
-
Sputum culture and drug sensitivity testing outcome among X-pert Mycobacterium tuberculosis/rifampicin-positive, rifampicin-resistant sputum: A retrospective study - Not all rifampicin resistance is multi-drug resistant. J Glob Antimicrob Resist. 2020 06; 21:434-438.
Score: 0,151
-
Efficacy and safety of delamanid in combination with an optimised background regimen for treatment of multidrug-resistant tuberculosis: a multicentre, randomised, double-blind, placebo-controlled, parallel group phase 3 trial. Lancet Respir Med. 2019 03; 7(3):249-259.
Score: 0,143
-
Bedaquiline-pretomanid-moxifloxacin-pyrazinamide for drug-sensitive and drug-resistant pulmonary tuberculosis treatment: a phase 2c, open-label, multicentre, partially randomised controlled trial. Lancet Infect Dis. 2024 Sep; 24(9):1003-1014.
Score: 0,052
-
Bedaquiline-Pretomanid-Linezolid Regimens for Drug-Resistant Tuberculosis. N Engl J Med. 2022 09 01; 387(9):810-823.
Score: 0,046
-
Dolutegravir twice-daily dosing in children with HIV-associated tuberculosis: a pharmacokinetic and safety study within the open-label, multicentre, randomised, non-inferiority ODYSSEY trial. Lancet HIV. 2022 09; 9(9):e627-e637.
Score: 0,046
-
An All-Oral 6-Month Regimen for Multidrug-Resistant Tuberculosis: A Multicenter, Randomized Controlled Clinical Trial (the NExT Study). Am J Respir Crit Care Med. 2022 May 15; 205(10):1214-1227.
Score: 0,045
-
Assessment of epidemiological and genetic characteristics and clinical outcomes of resistance to bedaquiline in patients treated for rifampicin-resistant tuberculosis: a cross-sectional and longitudinal study. Lancet Infect Dis. 2022 04; 22(4):496-506.
Score: 0,043
-
Bedaquiline, moxifloxacin, pretomanid, and pyrazinamide during the first 8 weeks of treatment of patients with drug-susceptible or drug-resistant pulmonary tuberculosis: a multicentre, open-label, partially randomised, phase 2b trial. Lancet Respir Med. 2019 12; 7(12):1048-1058.
Score: 0,038
-
Efficiency and safety of the combination of moxifloxacin, pretomanid (PA-824), and pyrazinamide during the first 8 weeks of antituberculosis treatment: a phase 2b, open-label, partly randomised trial in patients with drug-susceptible or drug-resistant pulmonary tuberculosis. Lancet. 2015 May 02; 385(9979):1738-1747.
Score: 0,027